日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Integrating multimodal management and molecular profiling in a patient with BRAF V600E-positive melanoma and brain metastases

对BRAF V600E阳性黑色素瘤伴脑转移患者进行多模式管理和分子谱分析

Gritsch, David; Fadden, Riley M; Mahar, Maura K; Khandsekar, Melin J; Oh, Kevin S; Cahil, Daniel P 3rd; Dunn, Gavin P; Sullivan, Ryan J; Brastianos, Priscilla K

STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer

STRATEGIC-1:一项针对不可切除的 RAS/BRAF 野生型转移性结直肠癌的多线、随机、开放标签的 GERCOR-PRODIGE-39 III 期试验

Chibaudel, Benoist; Dourthe, Louis-Marie; André, Thierry; Henriques, Julie; Bourgeois, Vincent; Etienne, Pierre-Luc; Desramé, Jérôme; Carola, Elisabeth; Dupuis, Olivier; Baba-Hamed, Nabil; Auby, Dominique; Louvet, Christophe; Maillard, Emmanuel; Romano, Olivier; Tournigand, Christophe; Garcia-Larnicol, Marie-Line; Shacham-Shmueli, Einat; Bird, Brian Healey; Ghiringhelli, François; de Gramont, Aimery

Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study

改良版 FOLFOXIRI 联合帕尼单抗一线治疗 RAS/BRAF 野生型转移性结直肠癌:III 期 TRIPLETE 研究的最终结果

Conca, Veronica; Rossini, Daniele; Antoniotti, Carlotta; Lonardi, Sara; Pietrantonio, Filippo; Moretto, Roberto; Antonuzzo, Lorenzo; Randon, Giovanni; Lavacchi, Daniele; Pozzo, Carmelo; Marmorino, Federica; Bergamo, Francesca; Tamburini, Emiliano; Passardi, Alessandro; Fazio, Roberta; Murgioni, Sabina; Borelli, Beatrice; Buonadonna, Angela; Germani, Marco Maria; Formica, Vincenzo; Carullo, Martina; Bordonaro, Roberto; Aprile, Giuseppe; Zaniboni, Alberto; Masi, Gianluca; Boni, Luca; Cremolini, Chiara

Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.

泛 RAF 抑制剂艾沙非尼靶向 BRAF II/III 类非小细胞肺癌,揭示 ARAF-KSR1 耐药性和联合治疗策略。

Manabe Tadashi, Bergo Hannah C, Li Qingtian, Wang Tim Sen, Severson Paul, Miller Nichol, Lee Catherine, Yay Donderici Elifnur, Zhang Nicole, Wu Wei, Chou Yu-Ting, Kerr Daniel L, Allegakoen Paul, Grandinetti Kathryn B, Soroceanu Liliana, Pelham Robert J, Martin Eric S, Murphy Eric A, Khanna Vishesh, Neal Joel W, Chen Christopher T, Kato Shumei, Williams Richard, Bivona Trever G

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial

比美替尼和恩科拉非尼治疗携带非V600E BRAF突变的晚期实体瘤:来自II期BEAVER试验的结果

April A N Rose #,Jennifer Maxwell #,Emmanuelle Rousselle #,Chantel L Mukonoweshuro,Islam E Elkholi,Melody Riaud,Marco Biondini,Erica Cianfarano,Isabel Soria-Bretones,Chantal Tobin,Meghan McGuire,Rhoda W Y Law,Andrew J Elia,Ben X Wang,Ian King,Tong Zhang,Trevor J Pugh,Zaid Saeed Kamil,Marcus Butler,Frances A Shepherd,Natasha B Leighl,Albiruni Abdul Razak,Aaron Hansen,Samuel D Saibil,Philippe L Bedard,Peter M Siegel,Lillian L Siu,David W Cescon,Anna Spreafico

BRAF(V600E) patient derived colon cancer organoids identify biomarkers of response to EGFR and BRAF inhibition and replicate clinical data

BRAF(V600E)患者来源的结肠癌类器官可识别EGFR和BRAF抑制剂疗效的生物标志物,并能重现临床数据。

Kotarac, Anna; Osumi, Hiroki; Malt, Alexander; Alp, Keziban Merve; Jarosch, Armin; Werner, Johannes; Benary, Manuela; Neumann, Christopher C M; Yao, Ryoji; Mertins, Philipp; Eils, Roland; Beule, Dieter; Sers, Christine; Keilholz, Ulrich; Ishaque, Naveed; Stintzing, Sebastian; Vecchione, Loredana

Dual targeting of BRAF(V600E) and ferroptosis results in synergistic anticancer activity via iron overload and enhanced oxidative stress.

BRAF(V600E) 和铁死亡的双重靶向作用通过铁过载和增强氧化应激产生协同抗癌活性。

Hu Jiangnan, Ghosh Chandrayee, Khaket Tejinder P, Yang Zhongyue, Tabdili Yasmine, Alamaw Eden D, Boufraqech Myriem, Dixon Scott J, Kebebew Electron

Optimal Adjuvant Therapy Selection for Chinese BRAF V600-Mutant Stage III Melanoma: A Multicenter Efficacy Comparison of Targeted Agents, Immunotherapy, and Combinatorial Strategies

中国BRAF V600突变型III期黑色素瘤最佳辅助治疗方案选择:靶向药物、免疫疗法和联合治疗策略的多中心疗效比较

Zhang, Rongcheng; Liang, Yao; Li, Jingjing; Chen, Qianqi; Ding, Ya; Wen, Xizhi; Zhao, Baiwei; Zheng, Wei; Wu, Junwan; Zhang, Qiong; Chen, Ziluan; Ding, Qiuyue; Chen, Linbin; Li, Renai; Li, Ke; Zhou, Qiming; Zhang, Xiaoshi; Li, Dandan

Unveiling a BRAF Signature Proficient in Accurately Capturing Oncogenic Activity and Guiding Prognostic Prediction Across Multiple Cancers

揭示一种能够准确捕捉致癌活性并指导多种癌症预后预测的BRAF特征

Yang, Kaidi; Fu, Shihui; Liang, Jingbing; Ding, Lijuan; You, Junhao; Li, Fang; Yuan, Ye; Bian, Xiu-Wu

Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)

针对共同的非突变抗原和共同的突变BRAF新抗原的黑色素瘤疫苗的I/II期临床试验,采用激动性CD40抗体(CDX-1140)和TLR3激动剂(poly-ICLC)

Ninmer, Emily K; Petroni, Gina R; Gastman, Brian R; Gaughan, Elizabeth M; Isaacs, James M; Haden, Kathleen; Kaur, Varinder; Wages, Nolan A; Chianese-Bullock, Kimberly A; Smith, Kelly T; Wright, Paul; Bryant, Jennifer; Dunlap-Brown, Marya; Engel, Jack A; Bekiranov, Stefan; Mauldin, Ileana S; Truong, Thach-Giao; Bullock, Timothy N J; Slingluff, Craig L Jr